



Efficacy of Platelet-Rich Fibrin on Outcome of 3rd Molar Extraction Mayo Hospital Lahore

¹Khadija Mushtaq, ²Umar Shah, ²Ali Raza, ²Hammad Javed

1Mayo Hospital Lahore

2UHS Lahore

Vol: 16/03, 511-522

Received: January 25, 2025 Accepted: March 02, 2025 Published: July 06, 2025

Abstract

There are many reasons for which extraction of teeth is performed, like caries making tooth non-restorable, periodontal disease, trauma, root fracture, acute infection impaction/orthodontic reasons. Impacted 3rd molar extraction is common surgical procedure performed by oral & maxillofacial surgeons. **Objective:** To compare the outcome of 3rd molar impaction surgery with and without platelet rich fibrin. **Study design:** Randomized controlled trial. **Setting:** Department of Oral & Maxillofacial Surgery, Mayo Hospital, Lahore. **Duration of study:** 06 months from 30th Dec 2022 to 30th Jun2023. **Subjects and methods:** 116 patients fulfilling the inclusion criteria were selected in this study. The patients were randomly divided in two groups, in group A, patients were undergone surgery with L-PRF. In group B, patients were undergone surgery without L-PRF. Data was recorded on structured proforma according to visual analogue scale and alveolar osteitis respectively. **Results:** In this present study, from 116 patients, it was observed that the minimum age was 17 years and maximum age was 35 years. The minimum pain score was 0 and maximum was 2 with mean and standard deviation was 0.74 ± 0.712 . There were 67 (57.8%) male patients and 49 (42.2%) were female patients. Alveolar Osteitis was developed in 15 (12.9%) patients while it was not developed in 101 (87.1%) patients. Significant association was found regarding Alveolar Osteitis in both groups with p-value = 0.013. **Conclusions:** Within the limitations of the present study, with PRF application after third molar impaction surgery is a good biologic material that reduces postoperative pain and alveolar osteitis as compared to without platelet rich fibrin. **Keywords:** Platelet-Rich Fibrin, Molar Extraction, Alveolar Osteitis



Introduction

Since the first description by Choukroun in 2000, platelet-rich fibrin (PRF) has become an important surgical adjuvant in oral surgical procedures. Infact, only after the publication of five important articles in 2006, this biomaterial gained highlight in the field of dental research.^{1,2} To date, more than 500 scientific articles have been published on this subject. Some of the possible recommendations to use this biomaterial in oral surgical procedures are third molar surgery, alveolar ridge preservation after tooth extractions, sinus lift procedure, repair of alveolar cleft, dental implants, surgical treatment of medication-related osteonecrosis of the jaw and treatment of oroantral communications.^{3,4}

PRF is a second generation of platelet concentrate produced without biochemical blood manipulation, and basically constituted for three key parameters: first, the presence of platelets and its activated growth factors that are substantial embedding into the fibrin matrix during the natural polymerization process; second, the presence of leucocytes and its cytokines that contribute for anti-infectious action and for immune regulation of the healing process; third, the density and complex organization of the fibrin matrix architecture produced by a natural polymerization, .^{5,6}

The strong fibrin architecture distinguishes it from other kinds of platelets concentrates, like platelet-rich plasma (PRP). This fibrin matrix seems responsible for the slow release of growth factors during proliferation stage of wound healing, over a period of 7-14 days, and it is composed of thin

fibers with micropores that can serve as scaffold for cell migration and differentiation. PRF is an important reservoir of numerous growth factors to promote angiogenesis, such as transforming growth factor (TGF- β) and vascular endothelial growth factor (VEGF). There are still large amounts of platelet-derived growth factors (PDGFs) in platelet α -granules, which act as an essential regulator for collagen production and mesenchymal cell migration and proliferation.^{7,8,9}

Extraction of mandibular third molars is one of the most frequently performed dental surgical procedures. While various surgical techniques and materials have been designed to accelerate the healing process after extraction, to date extractions specific to mandibular third molars remain those associated with the highest rate of potential complications. Specifically, alveolar osteitis (AO, dry socket) has been a well-known side effect following removal of mandibular third molars (especially those impacted) with well-known clinical manifestations including a partial or total disintegrated blood clot within the healing socket, resulting in prolonged inflammation, exposed bone, delayed healing, and gradually increasing severity of pain.^{10,11}

Reports from the literature suggest that while the incidence of AO has been reported relatively low in routine dental extractions, this rate has been reported much higher (3.9–29.6%) when focused specifically on mandibular third molars.^{12,13}

Therefore, precautions and effective strategies should be employed to minimize patient discomfort and improve clinical outcomes with many predisposing factors, including pre-existing



systemic diseases, operative technique, smoking, oral contraceptives, anticoagulant medication, and poor oral hygiene and/or pre-existing local infection, being identified as risk factors increasing the rate of occurrence.^{14,15}

One strategy that has gained popularity in recent years has been the use of platelet concentrates. While platelet rich plasma (PRP) was first utilized in regenerative medicine and dentistry owing to its supra-physiological doses of platelets and accompanying growth factors, more recently, its incorporation of anticoagulants has since been shown to interfere with the angiogenic and regenerative responses mediated by platelets. For these reasons, a second generation platelet concentrate termed platelet rich fibrin (PRF) has been more favourably utilized with anticoagulant removal. A number of randomized clinical studies in various avenues of dentistry have further demonstrated its ability to either promote hard or soft tissues.¹⁶



Methods

STUDY DESIGN: Randomized controlled trial

SETTING: Department of Oral & Maxillofacial Surgery, Mayo Hospital, Lahore.

DURATION: 6 months from 30th Dec 2022 to 30th Jun 2022.

SAMPLE SIZE: Sample size of 116 cases, 58 in each group is calculated with 80% power of study, 95% confidence level, pain score of 0 with PRF and 0.52 ± 1.41 without PRF.

SAMPLING TECHNIQUE: Non-probability, consecutive sampling

SAMPLE SELECTION

Inclusion Selection: Patients of age between 17-35 years, both genders, with impacted mandibular 3rd molar undergoing 3rd molar impaction surgery (as per operational definitions)

Exclusion criteria:

- Presence of peri-coronitis, peri-apical lesion with respect to impacted 3rd molar, opposite traumatic occluding/impinging upper 3rd molar
- Smoker
- Alcoholics, systemic disorders i.e. hypertension ($\geq 140/90$ mmHg), and diabetes (BSR > 200 mg/dl), taking chemotherapy, radiotherapy or immunosuppressive therapy for malignancy, osteoporosis or HIV positive patients.

DATA COLLECTION PROCEDURE: After taking approval from hospital ethical committee 116 patients fulfilling the inclusion criteria will be selected in the study from department of oral and maxillofacial surgery. They will be recruited in the study after written informed consent. The patient's demographics like

age, gender, and lateral side will be noted. Then patients will be randomly divided into two groups by using lottery method. In group A, patients will undergo surgery with L-

PRF. In group B, patients will undergo surgery without L-

PRF. Before surgical extraction, two 10 ml blood samples are harvested and centrifuged at 3000 rpm for 10 minutes. The product of centrifuge process will be taken to a tray/bowl in order to separate serum from fibrin during one minute. IANB, Lingual nerve block and long buccal nerve block will be given with 1-

2% lignocaine with epinephrine. Mandibular 3rd molar will be extracted by standard rules. The wound will be closed after blood clot formation in group B with vicryl 3/0 and in group A after placement of L-

PRF immediately with vicryl 3/0. Patients will be recalled on day 1, 3 and 7. Data will be recorded on structured proforma according to visual analogue scale and alveolar osteitis respectively (as per operational definition). All this information will be recorded through proforma (attached).

DATA ANALYSIS: All the collected information will be entered into SPSS Version 26. Quantitative variables like age, duration of procedure, and pain will be presented as mean $\pm$ SD.

Qualitative variables like gender, lateral side, and Alveolar Osteitis will be presented as frequency and percentages. Both groups will be compared for Alveolar Osteitis by using chi-square test and pain score by t-test. P-value ≤ 0.05 will be taken as significant. Data will be stratified for age, gender, lateral side, and duration of procedure. Post-stratification, both groups will be compared for outcome by using chi-square test and t-test respectively.



ineachstratum.P-

value $\leq$ 0.05willbetakenassignificant.



Results

Descriptive statistics was shown in table 1. Percentage of gender was shown in graph 1. Tables 2 and 3 show the descriptive statistics of lateral side and Alveolar Osteitis respectively. Significant association was found regarding Alveolar Osteitis in both groups with p-value = 0.013 (Table 4). The Alveolar Osteitis in both group (Group A (with L-PRF), Group B (without L-PRF)) was noted concerning age (below 25 years and above 25 years), it was found that there was a significant association for < 25 years old, but it was not significantly associated with ≥ 25 years old with p-value = 0.024 (Table 5). The Alveolar Osteitis in both group (Group A (with L-PRF), Group B (without L-PRF)) was noted concerning gender, it was found that there was no significant association for male, but it was significantly associated with female patients having p-value = 0.033 (Table 6). The Alveolar Osteitis in both group (Group A (with L-PRF), Group B (without L-PRF)) was noted concerning duration of procedure (below 25 min and above 25 min), it was found that there was no significant association between them (Table 7). By using independent sample t-test, comparison of mean pain score in both groups (Group A (with L-PRF), Group B (without L-PRF)) was applied, it was found that there was a significant difference between them having p-value as 0.001 (Table 8). By using independent sample t-test and stratification of age, it was found that there was significant difference in both groups (Group A (with L-PRF), Group B (without L-PRF)) regarding age and pain score (Table 9). Independent sample t-test was applied for both

groups (Group A (with L-PRF), Group B (without L-PRF)), there was significant difference between pain score and gender having p-value as 0.008 and 0.003 for male and female respectively (Table 10). It was found that there was significant difference in both groups (Group A (with L-PRF), Group B (without L-PRF)) regarding pain score and duration of procedure (Table 11).



Table 1. Descriptive Statistics

(n = 116)

	Minimum	Maximum	Mean	Std. Deviation
	17	35	25.99	4.898
ion of procedure	10	40	21.22	6.768
core	0	2	0.74	0.712



Graph 1. Pie chart of Gender






Table 2. Distribution of lateral side

Lateral side	Frequency	Percent
Left	45	38.8
Right	71	61.2
Total	116	100.0



Table 3. Distribution of Alveolar Osteitis

Alveolar Osteitis	Frequency	Percent
Developed	15	12.9
Not developed	101	87.1
Total	116	100.0



**Table 4. Stratification of Alveolar Osteitis with
respect to both groups
(n = 116)**

p	Alveolar Osteitis		Total	P-value
	Developed	Not developed		
p A (with L-PRF)	3	55	58	0.013
p B (without L-PRF)	12	46	58	
	15	101	116	

Chi-square test was applied.



**Table 5. Stratification of Alveolar Osteitis in both
groups with regards to age
(n = 116)**

Age	Group	Alveolar Osteitis		Total	p-value
		Developed	Not developed		
Ears	Group A (with L-2 PRF)		22	24	0.220
	Group B (without L-PRF)	5	19	24	
Ears	Group A (with L-1 PRF)		33	34	0.024
	Group B (without L-PRF)	7	27	34	
		15	101	116	



**Table 6. Stratification of Alveolar Osteitis in both
groups with regards to gender
(n = 116)**

Gender	Group	Alveolar Osteitis		Total	p-value
		Developed	Not developed		
Female	Group A (with L-PRF)	3	30	33	0.111
	Group B (without L-PRF)	8	26	34	
Male	Group A (with L-PRF)	0	25	25	0.033
	Group B (without L-PRF)	4	20	24	
Total		15	101	116	



**Table 7. Stratification of Alveolar Osteitis in both
groups with regards to duration of procedure
(n = 116)**

Duration of procedure	Group	Alveolar Osteitis		Total	p-value
		Yes	No		
5 min	Group A (with L-PRF)	2	42	44	0.141
	Group B (without L-PRF)	5	31	36	
5 min	Group A (with L-PRF)	1	13	14	0.083
	Group B (without L-PRF)	7	15	22	
Total		15	101	116	



**Table 8. Comparison of mean pain score in both
groups
(n = 116)**

Group	n	Mean $\pm$ SD	P-Value
Group A (with L-PRF)	58	0.48 $\pm$ 0.504	0.001
Group B (without L-PRF)	58	1.00 $\pm$ 0.795	

Independent T-test applied



**Table 9. Comparison of mean pain score in both
groups with respect to age
(N = 60)**

Age	Group	n	Mean $\pm$ SD	P-Value
25 years	Group A (with L-PRF)	24	0.38 $\pm$ 0.495	0.009
	Group B (without L-PRF)	24	0.92 $\pm$ 0.830	
35 years	Group A (with L-PRF)	34	0.56 $\pm$ 0.504	0.002
	Group B (without L-PRF)	34	1.06 $\pm$ 0.776	

Independent T-test applied



**Table 10. Comparison of mean pain score in both
groups with respect to Gender
(N = 60)**

Gender	Group	n	Mean $\pm$ SD	P-Value
Female	Group A (with L-PRF)	33	0.52 $\pm$ 0.508	0.008
	Group B (without L-PRF)	34	0.94 $\pm$ 0.736	
Male	Group A (with L-PRF)	25	0.44 $\pm$ 0.507	0.003
	Group B (without L-PRF)	24	1.08 $\pm$ 0.881	

Independent T-test applied



Table 11. Comparison of mean pain score in both groups with respect to duration of procedure (N = 60)

Duration of procedure	Group	n	Mean $\pm$ SD	P-Value
5 min	Group A (with L-PRF)	44	0.48 $\pm$ 0.505	0.044
	Group B (without L-PRF)	36	0.78 $\pm$ 0.797	
10 min	Group A (with L-PRF)	14	0.50 $\pm$ 0.519	0.001
	Group B (without L-PRF)	22	1.36 $\pm$ 0.658	

Independent T-test applied



Discussion

Significant association was found regarding Alveolar Osteitis in both groups with p-value = 0.013 (Table 4). The Alveolar Osteitis in both group (Group A (with L-PRF), Group B (without L-PRF)) was noted concerning age (below 25 years and above 25 years), it was found that there was a significant association for < 25 years old, but it was not significantly associated with $\geq$ 25 years old with p-value = 0.024 (Table 5). The Alveolar Osteitis in both group (Group A (with L-PRF), Group B (without L-PRF)) was noted concerning gender, it was found that there was no significant association for male, but it was significantly associated with female patients having p-value = 0.033 (Table 6). The Alveolar Osteitis in both group (Group A (with L-PRF), Group B (without L-PRF)) was noted concerning duration of procedure (below 25 min and above 25 min), it was found that there was no significant association between them (Table 7). By using independent sample t-test, comparison of mean pain score in both groups (Group A (with L-PRF), Group B (without L-PRF)) was applied, it was found that there was a significant difference between them having p-value as 0.001 (Table 8). By using independent sample t-test and stratification of age, it was found that there was significant difference in both groups (Group A (with L-PRF), Group B (without L-PRF)) regarding age and pain score (Table 9). Independent sample t-test was applied for both groups (Group A (with L-PRF), Group B (without L-PRF)), there was significant difference between pain score and gender having p-value as 0.008 and 0.003 for male and female respectively (Table

10). It was found that there was significant difference in both groups (Group A (with L-PRF), Group B (without L-PRF)) regarding pain score and duration of procedure (Table 11).

Platelet-rich fibrin is characterized by the slow polymerization during its preparation that generates a fibrin network very similar to the natural one that enhances cell migration and proliferation. Being a reservoir of platelets, leukocytes, cytokines and immune cells, PRF is reported to allow slow release of cytokines; TGF, PDGF, VEGF, and EGF which play a critical role in angiogenesis and tissue healing and cicatrization. PRF also reported to enhance angiogenesis, support immunity, and to enhance the coverage of injured tissues through its positive effect on epithelial cells and fibroblasts. Although, PRF preparation is a simple, inexpensive process, and requires no additives, rapid blood handling is an important factor in success of its preparation. Failure in quick handling of the blood sample results in a diffuse polymerized fibrin within the glass tube and only a small blood clot without consistency will be obtained. In previous study, considering the socket complications, PRF significantly reduced the incidence of alveolar osteitis (AO) compared with the control group ($P = 0.037$). However, there were no significant differences between the two groups regarding the incidence of infected or inflamed sockets ($P = 1.00$ and 0.312 respectively).

Complications following third molar surgery are not uncommon. Pain and delayed healing are perhaps the most frequently encountered complications. AO is a painful and relatively common complication that necessitates



intervention for treatment. The incidence of AO following removal of ILTMs varies from 7 to 32.6%. In accordance with the previous studies, an incidence of AO was found in Group A (with L-PRF) was 5% (3/58) and in Group B (without L-PRF) was found in 20 (12/58) in the present study. The positive role of PRF in the prevention of AO was also reported by Hoaglin and Lines and Eshgbpour et al.¹⁷

Relief of postoperative pain is an essential criterion in the overall success of tooth extraction. In addition, most of the potential postoperative complications are in fact manifested as pain. In the present study, the degree of pain was measured using the VAS for pain relief. This study revealed that L-PRF significantly reduced postoperative pain following surgical removal of impacted third molars. This is in agreement with other studies¹⁸. Hoaglin and Lines investigated the number of alveolar infection including AO with/without PRF. It was found that placement of PRF within the extraction site was associated with a 1.0 % rate of AO versus 9.5 % in the control site (nearly a 10 fold reduction). There was a significant reduction in pain associated with AO at 3 and 7 days post-PRF placement, a marked decrease in the degree of inflammation at 3 days and better wound healing by the 2nd week.¹⁹ Similarly, Yüce and colleagues found that PRF application in already existing AO cases demonstrated rapidly and continually reduced pain intensity at each respective time when compared to the control^{20 17}

Conclusion

Within the limitations of the present study, with PRF application after third molar impaction surgery is a good biologic material that reduces postoperative pain and alveolar osteitis as compared to without platelet rich fibrin.

References

1. Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part V: Histologic evaluations of PRF effects on bone allograft maturation in sinus lift. *Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics*. 2006;101(3):299-303.
2. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? *Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics*. 2006;101(3):e51-5.
3. Mazor Z, Horowitz RA, Del Corso M, Prasad HS, Rohrer MD, Ehrenfest DM. Sinus floor augmentation with simultaneous implant placement using Choukroun's platelet-rich fibrin as the sole grafting material: A radiologic and histologic study at 6 months. *Journal of periodontology*. 2009;80(12):2056-64.
4. Eshghpour M, Dastmalchi P, Nekooei AH, Nejat A. Effect of platelet rich fibrin on frequency of alveolar osteitis following mandibular third molar surgery: A doubleblinded randomized clinical trial. *Journal of Oral and Maxillofacial Surgery*. 2014;72(8):1463-7.
5. Pirraco RP, Reis RL, Marques AP. Effect of monocytes/macrophages on the early osteogenic differentiation of hBMSCs. *J Tissue Eng Regen Med*. 2013;7(5):392-400.
6. Dohan Ehrenfest DM, Del Corso M, Diss A, Mouhyi J, Charrier JB. Threedimensional architecture and cell composition of a Choukroun's platelet-rich fibrin clot and membrane. *Journal of periodontology*. 2010;81(4):546-55.
7. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol*. 2009;27(3):158-67.
8. Kobayashi E, Fluckiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B, et al. Comparative release of growth factors from PRP, PRF, and advanced-PRF. *Clinical oral investigations*. 2016;20(9):2353-60.
9. Fujioka-Kobayashi M, Miron RJ, Hernandez M, Kandalam U, Zhang Y, Choukroun J. Optimized Platelet-Rich Fibrin With the Low-Speed Concept: Growth Factor Release, Biocompatibility, and Cellular Response. *J Periodontol*. 2017;88(1):112-21.
10. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol*. 2009;27(3):158-67.
11. Göktaş Ö, Satılmış , leucocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol*. 2009;27(3):158-67.
12. 13. 14. 15. Göktaş Ö, Satılmış , T, Garip H, Gönül O, Göker K. A comparison of the effects of midazolam/fentanyl and midazolam/tramadol for conscious



- intravenous sedation during third molar extraction. *J Oral Maxillofac Surg* 2011;69:1594–9.
12. Bui CH, Seldin EB, Dodson TB. Types, frequencies, and risk factors for complications after third molar extraction. *J Oral Maxillofac Surg* 2003;61:1379–89.
13. Schwartz-Arad D, Lipovsky A, Pardo M, Adut O, Dolev E. Interpretations of complications following third molar extraction. *Quintessence Int* 2018;49.
14. Landucci A, Wosny A, Uetanabaro L, Moro A, Araujo M. Efficacy of a single dose of low-level laser therapy in reducing pain, swelling, and trismus following third molar extraction surgery. *Int J Oral Maxillofac Surg* 2016;45:392–8.
15. Gocmen G, Gonul O, Oktay NS, Yarat A, Goker K. The antioxidant and anti-inflammatory efficiency of hyaluronic acid after third molar extraction. *J Cranio-Maxillofacial Surg* 2015;43:1033–7.
16. Kaul RP, Godhi SS, Singh A. Autologous platelet rich plasma after third molar surgery: a comparative study. *J Maxillofac Oral Surg* 2012;11:200–5.
17. Jafarian M, Etebarian A. Reasons for extraction of permanent teeth in general dental practices in Tehran, Iran. *Med Princ Pract*. 2013;22(3):239–44.
18. Alesia K, Khalil HS. Reasons for and patterns relating to the extraction of permanent teeth in a subset of the Saudi population. *Clin Cosmet Investig Dent*. 2013;5:51–6.
19. Jung YH, Cho BH. Radiographic evaluation of third molar development in 6- to 24-year-olds. *Imaging Sci Dent*. 2014;44(3):185–91.
20. Tuteja M, Bahrwani S, Balaji P. An evaluation of third molar eruption for assessment of chronologic age: A panoramic study. *J Forensic Dent Sci*. 2012;4(1):13–8.